Verisante Technology Inc
TSXV:VER.HView on Over The Counter Market

  • LAST PRICE
    0.0150
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    0.0150/ 8
  • Open / Previous Close
    --- / 0.0150
  • Day Range
    ---
  • 52 Week Range
    0.0100
    0.0750
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 31, 2024

      Show headlines and story abstract

    • 5:23PM ET on Thursday Oct 31, 2024 by Dow Jones
      Companies Mentioned: VER.H

      To date approximately $6.3 million has been invested in the development of SBC003. Utilizing independent CROs, SunRegen has completed mice and monkey studies on the safety and efficacy of SBC003 with highly encouraging results and is now at the Investigational New Drug (IND) application stage of the FDA approval process. The next stage is to conduct toxicity, safety and formulation tests in preparation for a Phase II human clinical study. SunRegen uses independent CROs to perform its studies to comply with strict regulatory requirements and to operate more efficiently with a reduced overhead and headcount. More information about SunRegen is available on the company's website at www.sunregen.ch.

Peers Headlines

No documents available